Skip to content

Cinven Nears More Than $2.5 Billion Deal for BioAgilytix

Updated on

Buyout firm Cinven is nearing a deal to acquire BioAgilytix in a transaction valuing the drug-research services company at more than $2.5 billion, according to people familiar with the matter. 

An agreement could be announced as soon as the coming days, the people said, asking not to be identified because the information is private. BioAgilytix’s owner, investment firm Cobepa, plans to keep a stake in the business after the deal, according to the people.